» Articles » PMID: 28348065

Genomic Disorders and Neurocognitive Impairment in Pediatric CKD

Overview
Specialty Nephrology
Date 2017 Mar 29
PMID 28348065
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Children with CKD are at increased risk for neurocognitive impairment, but whether neurocognitive dysfunction is solely attributable to impaired renal function is unclear. Data from the CKD in Children Study Chronic Kidney Disease in Children (CKiD) Study indicate that a subset of children with CKD have unsuspected genomic disorders that predispose them to organ malformations and neurocognitive impairment. We therefore tested whether the CKiD Study participants with genomic disorders had impaired neurocognitive performance at enrollment. Compared with noncarriers (=389), children with genomic disorders (=31) scored significantly poorer on all measures of intelligence, anxiety/depressive symptoms, and executive function (differences of 0.6-0.7 SD; =1.2×10-2.4×10). These differences persisted after controlling for known modifiers, including low birth weight, maternal education, seizure disorder, kidney disease duration, and genetically defined ancestry. The deleterious effect of genomic disorders on neurocognitive function was significantly attenuated in offspring of mothers with higher education, indicating the potential for modification by genetic and/or environmental factors. These data indicate that impaired neurocognitive function in some children with CKD may be attributable to genetic lesions that affect both kidney and neurocognitive development. Early identification of genomic disorders may provide opportunity for early diagnosis and personalized interventions to mitigate the effect on neurocognitive function.

Citing Articles

Age-Related Changes in Brain Structure in Pediatric Chronic Kidney Disease.

van der Plas E, Nelson E, Becknell B, Dawson A, Wilson C, Dawson J JAMA Netw Open. 2025; 8(2):e2457601.

PMID: 39899296 PMC: 11791706. DOI: 10.1001/jamanetworkopen.2024.57601.


The role of genomic disorders in chronic kidney failure of undetermined aetiology ≤50 years.

Granhoj J, Pedersen K, Aagaard M, Graakjaer J, Lildballe D, Birn H Clin Kidney J. 2024; 17(7):sfae166.

PMID: 39021813 PMC: 11252669. DOI: 10.1093/ckj/sfae166.


Revealing novel biomarkers for diagnosing chronic kidney disease in pediatric patients.

Benito S, Unceta N, Maciejczyk M, Sanchez-Ortega A, Taranta-Janusz K, Szulimowska J Sci Rep. 2024; 14(1):11549.

PMID: 38773318 PMC: 11109104. DOI: 10.1038/s41598-024-62518-w.


Mental health and social-emotional functioning in children and adolescents with chronic kidney disease.

Kogon A, Hooper S Pediatr Nephrol. 2023; 39(7):2015-2031.

PMID: 37878136 DOI: 10.1007/s00467-023-06151-1.


Circulating Metabolomic Associations with Neurocognitive Outcomes in Pediatric CKD.

Lee A, Xu Y, Hooper S, Abraham A, Hu J, Xiao R Clin J Am Soc Nephrol. 2023; 19(1):13-25.

PMID: 37871960 PMC: 10843217. DOI: 10.2215/CJN.0000000000000318.


References
1.
El-Hattab A, Smolarek T, Walker M, Schorry E, Immken L, Patel G . Redefined genomic architecture in 15q24 directed by patient deletion/duplication breakpoint mapping. Hum Genet. 2009; 126(4):589-602. PMC: 3669685. DOI: 10.1007/s00439-009-0706-x. View

2.
South S, Lee C, Lamb A, Higgins A, Kearney H . ACMG Standards and Guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013. Genet Med. 2013; 15(11):901-9. DOI: 10.1038/gim.2013.129. View

3.
Brunetti-Pierri N, Berg J, Scaglia F, Belmont J, Bacino C, Sahoo T . Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. Nat Genet. 2008; 40(12):1466-71. PMC: 2680128. DOI: 10.1038/ng.279. View

4.
Hernandez E, Loza R, Vargas H, Jara M . Depressive symptomatology in children and adolescents with chronic renal insufficiency undergoing chronic dialysis. Int J Nephrol. 2011; 2011:798692. PMC: 3177095. DOI: 10.4061/2011/798692. View

5.
Miller D, Adam M, Aradhya S, Biesecker L, Brothman A, Carter N . Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010; 86(5):749-64. PMC: 2869000. DOI: 10.1016/j.ajhg.2010.04.006. View